Bd-becton Dickinson

BALTIMORE, November 24, 2011 - - New, Fully Automated BD MAX™ MRSA Assay Rapidly Identifies Patients Colonized with Deadly Superbug BD Diagnostics, a segment of BD (Becton, Dickinson and Company), today announced that it obtained CE Marking for the BD MAX™ MRSA Assay to rapidly and accurately identify methicillin-resistant Staphylococcus aureus (MRSA) in patients.

BALTIMORE and BRESCIA, Italy, August 18, 2011 - -Agreement WillAccelerate Assays to Market for Immunocompromised and Transplant Patients in Europe BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company), and Biodiversity SpA, a private biotechnology company focusing on molecular diagnostics, announced today a regional collaboration to develop and commercialize a comprehensive molecular diagnostic menu for immunocompromised patients on the BD MAX™ System.

FRANKLIN LAKES, New Jersey, August 15, 2011 - BD Medical, a segment of BD (Becton, Dickinson and Company), today announced the launch of the BD Emerald™ Syringe portfolio designed to meet emerging needs in medication delivery while addressing environmental impact by reducing material.

BALTIMORE and CAMBRIDGE, England, August 3, 2011 - - Agreement Marks Significant Planned Addition to System's Content-Rich Test Menu BD Diagnostics, a segment of global medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX), and Lab21, a global leader in personalised healthcare, announced today a collaboration to develop a state-of-the-art molecular diagnostic assay to detect the life-threatening Aspergillus fungus using the new fully automated BD MAX™ Molecular Testing System.

MILAN, May 6, 2011 - BD Diagnostics, a segment of BD (Becton, Dickinson and Company) (NYSE: BDX), today announced the European launch of the BD MAX(TM) Open System for molecular testing, which will enable laboratories to run both laboratory and BD- developed assays and offer enhanced testing services that elevate the standards of care at their institutions.